Collects safety data on turoctocog alfa pegol in people with haemophilia A
Records side effects of turoctocog alfa pegol in people with haemophilia A.
Plain-language title generated from the registry record
Registry title: Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol
Key facts
- Where
- Søborg, DenmarkSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial uses safety data from the EUHASS registry on people with haemophilia A treated with turoctocog alfa pegol. Patients take on no extra burden.
- Sex
- All sexes can join.
Read by machine on 12 November 2026.
Where in Denmark
- SøborgHospital not named in the registryNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT04682145
- Record updated
- 8 October 2026
- Original description
This non-interventional study concerns a safety data collection based on adverse event data from a third-party registry (European Haemophilia Safety Surveillance System, EUHASS) that includes information about adverse events from patients with haemophilia A treated with turoctocog alfa pegol. There is no extra burden to the patients by participating in this registry-based data collection.Read full original descriptionShow less
Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol
This non-interventional study concerns a safety data collection based on adverse event data from a third-party registry (European Haemophilia Safety Surveillance System, EUHASS) that includes information about adverse events from patients with haemophilia A treated with turoctocog alfa pegol. There is no extra burden to the patients by participating in this registry-based data collection.
Inclusion: Participation in the European Haemophilia Safety Surveillance System (EUHASS).
Exclusion: N/A.